Cargando…

Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer

PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alberini, Jean-Louis, Boisgard, Raphaël, Guillermet, Stéphanie, Siquier, Karine, Jego, Benoît, Thézé, Benoît, Urien, Saik, Rezaï, Keyvan, Menet, Emmanuelle, Maroy, Renaud, Dollé, Frédéric, Kühnast, Bertrand, Tavitian, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927598/
https://www.ncbi.nlm.nih.gov/pubmed/26630973
http://dx.doi.org/10.1007/s11307-015-0916-7
_version_ 1782440284199583744
author Alberini, Jean-Louis
Boisgard, Raphaël
Guillermet, Stéphanie
Siquier, Karine
Jego, Benoît
Thézé, Benoît
Urien, Saik
Rezaï, Keyvan
Menet, Emmanuelle
Maroy, Renaud
Dollé, Frédéric
Kühnast, Bertrand
Tavitian, Bertrand
author_facet Alberini, Jean-Louis
Boisgard, Raphaël
Guillermet, Stéphanie
Siquier, Karine
Jego, Benoît
Thézé, Benoît
Urien, Saik
Rezaï, Keyvan
Menet, Emmanuelle
Maroy, Renaud
Dollé, Frédéric
Kühnast, Bertrand
Tavitian, Bertrand
author_sort Alberini, Jean-Louis
collection PubMed
description PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), single photon emission tomography (SPECT) with [(99m)Tc]TcO(4) ([(99m)Tc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [(18)F]FDG and [(99m)Tc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed. RESULTS: All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [(99m)Tc]TEC and [(18)F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [(18)F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [(18)F]FDG and [(99m)Tc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week(−1) in untreated, doxorubicin, and docetaxel groups, respectively. CONCLUSIONS: Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [(18)F]FDG-PET and [(99m)Tc]TEC SPECT monitor tumor response to chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-015-0916-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4927598
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-49275982016-07-13 Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer Alberini, Jean-Louis Boisgard, Raphaël Guillermet, Stéphanie Siquier, Karine Jego, Benoît Thézé, Benoît Urien, Saik Rezaï, Keyvan Menet, Emmanuelle Maroy, Renaud Dollé, Frédéric Kühnast, Bertrand Tavitian, Bertrand Mol Imaging Biol Research Article PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), single photon emission tomography (SPECT) with [(99m)Tc]TcO(4) ([(99m)Tc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [(18)F]FDG and [(99m)Tc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed. RESULTS: All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [(99m)Tc]TEC and [(18)F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [(18)F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [(18)F]FDG and [(99m)Tc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week(−1) in untreated, doxorubicin, and docetaxel groups, respectively. CONCLUSIONS: Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [(18)F]FDG-PET and [(99m)Tc]TEC SPECT monitor tumor response to chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-015-0916-7) contains supplementary material, which is available to authorized users. Springer US 2015-12-02 2016 /pmc/articles/PMC4927598/ /pubmed/26630973 http://dx.doi.org/10.1007/s11307-015-0916-7 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Alberini, Jean-Louis
Boisgard, Raphaël
Guillermet, Stéphanie
Siquier, Karine
Jego, Benoît
Thézé, Benoît
Urien, Saik
Rezaï, Keyvan
Menet, Emmanuelle
Maroy, Renaud
Dollé, Frédéric
Kühnast, Bertrand
Tavitian, Bertrand
Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title_full Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title_fullStr Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title_full_unstemmed Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title_short Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
title_sort multimodal in vivo imaging of tumorigenesis and response to chemotherapy in a transgenic mouse model of mammary cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927598/
https://www.ncbi.nlm.nih.gov/pubmed/26630973
http://dx.doi.org/10.1007/s11307-015-0916-7
work_keys_str_mv AT alberinijeanlouis multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT boisgardraphael multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT guillermetstephanie multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT siquierkarine multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT jegobenoit multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT thezebenoit multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT uriensaik multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT rezaikeyvan multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT menetemmanuelle multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT maroyrenaud multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT dollefrederic multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT kuhnastbertrand multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer
AT tavitianbertrand multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer